U.S., July 23 -- ClinicalTrials.gov registry received information related to the study (NCT07076407) titled 'A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3)' on July 14.
Brief Summary: X-NOVA3 is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the clinical efficacy, safety, and tolerability of azetukalner as a monotherapy in adult participants diagnosed with Major Depressive Disorder (MDD)
Study Start Date: July 08
Study Type: INTERVENTIONAL
Condition:
Major Depressive Disorder
Intervention:
DRUG: Azetukalner
Azetukalner 20 mg taken orally once a day with food (with the evening meal when possible) for 6 weeks
DRUG: Placebo
Placebo taken orally once a da...